Cayman Etifoxine-13C-d3

Etifoxine-¹³C-d₃ is intended for use as an internal standard for the quantification of etifoxine (Item No. ) by GC- or LC-MS. Etifoxine is a positive allosteric modulator of α₁β₂γ₂ and α₁β₃γ₂ subunit-containing GABA_A receptors. It selectively increases GABA-induced currents in X. laevis oocytes expressing α₁β₂γ₂ or α₁β₃γ₂ over α₁β₁γ₂ subunit-containing receptors at 20 µM. Etifoxine inhibits binding of the GABA_A receptor agonist muscimol in rat corticol membranes with a K_d value of 23 nM in a radioligand binding assay. It increases NGF-induced neurite outgrowth in PC12 cells when used at a concentration of 20 µM. Etifoxine (12.5 mg/kg, i.p.) increases the percentage of time spent in the open arms of the elevated plus maze in high-anxiety BALB/cByJ, but not C57BL/6, mice, indicating anxiolytic-like activity. It increases the seizure threshold in a mouse model of seizures induced by picrotoxin (Item No. ) with a minimum effective dose (MED) of 75 mg/kg. Etifoxine (50 mg/kg, i.p.) also increases the paw withdrawal threshold on the ipsilateral side in a rat model of rheumatoid arthritis induced by complete Freunds adjuvant.

WARNING This product is not for human or veterinary use.